Active Ingredient: Bamlanivimab
Treatment of mild-to-moderate COVID-19 in patients aged ≥12 years who weigh ≥40 kg with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
High-risk defined as meeting at least 1 of these criteria:
Chronic kidney disease
Receiving immunosuppressive treatment
Age ≥65 years
Age ≥55 years and have cardiovascular disease, hypertension, or COPD/chronic respiratory disease
For this indication, competent medicine agencies globally authorize below treatments:
700 - 700 mg
From 700 To 700 mg once every day
700 mg as a single IV infusion over 60 minutes
Administer as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset in patients at high-risk for progressing to severe COVID-19 and/or hospitalization.
Single IV infusion over 60 minutes.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.